Cross-Sector entity
Concentra is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 124-day span. gene-therapy accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder.
2 verified stories tracked
Last mentioned: Jun 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Concentra is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.1 stories per week across a 124-day span. gene-therapy accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. This profile follows 2 Cross-Sector stories mentioning Encompass Health across the period from February 19, 2026 to June 22, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Encompass Health. Shared-story counts are live from our verified record — not editorial picks.
Ocular Therapeutix's commercial revenues are shrinking amid massive losses, while Prime Medicine's Prime Editing platform promises a DNA cure but lacks any product revenue. Both illustrate the extreme risk-reward calculus of biotech investing, where a single clinical win can eclipse years of cash burn.
Source: Pamela Kock (us) · Pamela Kock (us)
Select Medical (NYSE: SEM) has revised its fiscal year 2026 earnings outlook, reflecting a stabilized post-acute care environment and improved labor dynamics. The update underscores the company's confidence in its specialized hospital and outpatient rehabilitation segments through the mid-decade.
Source: themarketsdaily.com · dailypolitical.com
